Vero Biotech wins FDA approval for inhaled nitric oxide delivery with anesthesia in the OR

The Genosyl system. [Image from the Vero Biotech website]Vero Biotech announced that the FDA approved its second-generation Genosyl system for use with rebreathing anesthesia in the operating room setting.

Atlanta-based Vero Biotech designed Genosyl for inhaled nitric oxide (iNO) delivery. This approval covers the second-generation Genosyl device. The third-generation device — which recently received FDA approval — has not yet been tested with rebreathing anesthesia. The company expects data for this setting available for the newer system in the first quarter of this year.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

FDA approves next-gen inhaled nitric oxide delivery system from Vero Biotech

[Image courtesy of Vero Biotech]Vero Biotech announced that it received FDA approval for its latest-generation tankless inhaled nitric oxide (iNO) delivery system.

Atlanta-based Vero Biotech developed its third-generation Genosyl delivery system for respiratory therapists. Its new features include faster dosing, simpler workflow and operational efficiency.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

FDA approves next-gen inhaled nitric oxide delivery system from Vero Biotech

[Image courtesy of Vero Biotech]Vero Biotech announced that it received FDA approval for its latest-generation tankless inhaled nitric oxide (iNO) delivery system.

Atlanta-based Vero Biotech developed its third-generation Genosyl delivery system for respiratory therapists. Its new features include faster dosing, simpler workflow and operational efficiency.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0